

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-10: cancelled.

11. (Original) An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
 - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
 - (g) a variant of SEQ ID NO:Y;
 - (h) an allelic variant of SEQ ID NO:Y; or
 - (i) a species homologue of the SEQ ID NO:Y.
12. (Original) The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

Claims 13-18: cancelled

19. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. (Original) A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

Claims 21-23: cancelled.

24. (Original) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

25. (New) An isolated protein comprising amino acid residues 1 to 627 of SEQ ID NO: 125.

26. (New) The isolated protein of claim 25 which comprises amino acid residues 2 to 627 of SEQ ID NO: 125.

27. (New) The isolated protein of claim 25 which comprises amino acid residues 27 to 627 of SEQ ID NO: 125.

28. (New) The protein of claim 25 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 125.

29. (New) A composition comprising the protein of claim 25 and an acceptable carrier.

30. (New) An isolated protein produced by the method comprising:

(a) expressing the protein of claim 25 by a cell; and

(b) recovering said protein.

31. (New) An isolated protein comprising the amino acid sequence of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
32. (New) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544, excepting the N-terminal methionine.
33. (New) The isolated protein of claim 31 which comprises the amino acid sequence of the secreted portion of the polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
34. (New) The protein of claim 31 which further comprises a polypeptide sequence heterologous to the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
35. (New) A composition comprising the protein of claim 31 and an acceptable carrier.
36. (New) An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 31 by a cell; and
 - (b) recovering said protein.
37. (New) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of amino acid residues 1 to 627 of SEQ ID NO: 125.
38. (New) The isolated polypeptide of claim 37, wherein said first polypeptide is at least 95% identical to said second polypeptide.
39. (New) The protein of claim 37 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 125.

40. (New) A composition comprising the protein of claim 37 and an acceptable carrier.
41. (New) An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 37 by a cell; and
 - (b) recovering said protein.
42. (New) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
43. (New) The isolated polypeptide of claim 42, wherein said first polypeptide is at least 95% identical to said second polypeptide.
44. (New) The protein of claim 42 which further comprises a polypeptide sequence heterologous to the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
45. (New) A composition comprising the protein of claim 42 and an acceptable carrier.
46. (New) An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 42 by a cell; and
 - (b) recovering said protein.
47. (New) An isolated protein consisting of at least 30 contiguous amino acid residues of amino acid residues 1 to 627 of SEQ ID NO: 125.
48. (New) The isolated protein of claim ~~47~~ which consists of at least 50 contiguous amino acid residues of amino acid residues 1 to 627 of SEQ ID NO: 125.
49. (New) The protein of claim ~~47~~ which further comprises a polypeptide sequence heterologous to SEQ ID NO: 125.
50. (New) A composition comprising the protein of claim ~~47~~ and an acceptable carrier.

51. (New) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 47 by a cell; and
 - (b) recovering said protein.
52. (New) An isolated protein consisting of at least 30 contiguous amino acid residues of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
53. (New) The isolated protein of claim 52 which consists of at least 50 contiguous amino acid residues of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
54. (New) The protein of claim 52 which further comprises a polypeptide sequence heterologous to the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
55. (New) A composition comprising the protein of claim 52 and an acceptable carrier.
56. (New) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 52 by a cell; and
 - (b) recovering said protein.